Mereo Biopharma Group PLC
NASDAQ:MREO
Mereo Biopharma Group PLC
Additional Paid In Capital
Mereo Biopharma Group PLC
Additional Paid In Capital Peer Comparison
Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors
Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Mereo Biopharma Group PLC
NASDAQ:MREO
|
Additional Paid In Capital
£254.3m
|
CAGR 3-Years
28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Additional Paid In Capital
$987.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Additional Paid In Capital
$1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Additional Paid In Capital
$894.6m
|
CAGR 3-Years
42%
|
CAGR 5-Years
236%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Additional Paid In Capital
£1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Additional Paid In Capital
£179.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
See Also
What is Mereo Biopharma Group PLC's Additional Paid In Capital?
Additional Paid In Capital
254.3m
GBP
Based on the financial report for Dec 31, 2022, Mereo Biopharma Group PLC's Additional Paid In Capital amounts to 254.3m GBP.
What is Mereo Biopharma Group PLC's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 3Y
28%
Over the last year, the Additional Paid In Capital growth was 3%. The average annual Additional Paid In Capital growth rates for Mereo Biopharma Group PLC have been 28% over the past three years .